CureVac (NASDAQ:CVAC) Sees Significant Increase in Short Interest

CureVac (NASDAQ:CVAC - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,850,000 shares, an increase of 19.5% from the March 15th total of 4,060,000 shares. Based on an average trading volume of 812,400 shares, the short-interest ratio is presently 6.0 days. Approximately 5.2% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research note on Friday, February 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CVAC. Two Sigma Advisers LP bought a new stake in shares of CureVac during the fourth quarter valued at approximately $48,000. Jump Financial LLC bought a new stake in shares of CureVac during the 4th quarter valued at $55,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of CureVac in the 4th quarter worth about $66,000. Barclays PLC purchased a new stake in shares of CureVac in the 3rd quarter worth about $67,000. Finally, XTX Topco Ltd increased its stake in shares of CureVac by 90.2% in the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock worth $83,000 after acquiring an additional 11,553 shares in the last quarter. Hedge funds and other institutional investors own 17.26% of the company's stock.

CureVac Trading Up 1.9 %

NASDAQ:CVAC traded up $0.06 during trading hours on Monday, hitting $3.18. The company had a trading volume of 304,241 shares, compared to its average volume of 807,818. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a 50-day moving average price of $3.08 and a 200 day moving average price of $3.17. The company has a market capitalization of $713.39 million, a PE ratio of 5.78 and a beta of 2.48. CureVac has a 52 week low of $2.22 and a 52 week high of $5.28.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The company had revenue of $15.44 million for the quarter, compared to the consensus estimate of $6.40 million. On average, equities research analysts predict that CureVac will post 0.72 EPS for the current fiscal year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.